GTBIF — Green Thumb Industries Inc.

Is GTBIF overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Oversold As of October 3, 2026

Green Thumb Industries Inc. (GTBIF) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $6.61. The rating moved from Neutral to Oversold on October 3, 2026.

See all oversold Healthcare stocks →

AI analysis

Green Thumb Industries Inc. (GTBIF) displays a mixed near-term outlook: a solid multi-state retail and branded-product platform supports medium-term growth if state legalization and same-store sales trends improve, but the stock is vulnerable in the current risk-off macro environment and to sector-specific regulatory, tax and banking constraints. Limited near-term visibility on earnings/cash flow and heavier industry competition mean upside is contingent on clearer positive catalysts (policy progress, better operating metrics, or improved access to capital). Monitor state legalization developments, same-store sales and margin trends, and any changes to federal banking/tax treatment for signs of a directional shift.

Key factors

  • Established multi-state retail footprint and branded consumer products that provide revenue diversification across markets and formats
  • Recent cautious macro tone (risk-off flows, light volumes) likely to weigh near-term discretionary and speculative demand for cannabis equities
  • Regulatory tailwinds from incremental state-level legalization remain a medium-term growth driver but progress is uneven and timing is uncertain
  • Operational scale benefits (supply chain, cultivation, manufacturing and retail integration) support margin recovery if same-store sales and wholesale demand stabilize
  • Limited visibility into near-term earnings and cash flow sequencing increases sensitivity to capital markets conditions for financing and M&A
  • Price level (~$6.61) already reflects a mix of growth expectations and regulatory/industry risk, leaving upside dependent on clearer catalysts (policy, materially better comps, positive guidance)

Risks

  • Federal illegality and banking/finance frictions that increase operating costs, constrain capital access, and complicate interstate commerce
  • State-level regulatory changes, tax/excise increases, or licensing disputes that can materially reduce margins or curtail market access
  • Intense competition from MSOs and local operators driving price compression in wholesale and retail channels
  • Macroeconomic risk-off environment reducing investor appetite for growth/sector-risk assets and limiting access to equity financing
  • Supply chain disruption or crop/cultivation issues that could hit product availability and margins
  • High effective tax rates for cannabis companies (e.g., 280E analogs) that limit reported profitability and cash flow
  • Consumer demand volatility and potential substitution or downward price pressure from illicit markets and adjacent products (CBD/derivatives)
  • Limited social sentiment and research coverage increases information asymmetry and short-term trading volatility

See today's live rating, score and targets

Members see the live hourly rating for GTBIF — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.